Trade BCAX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Bicara Therapeutics Inc. (BCAX) is trading at US$24.93, up 0.39% today as of Aug 28, 09:30 EDT. The company has a market capitalisation of US$1.58B. Over the past 52 weeks, BCAX has traded between US$10.30 and US$30.99. On Syfe you can trade BCAX with $0 commission and add it to your watchlist.
| Previous close | US$24.83 |
|---|---|
| Market cap | US$1.58B |
| 52-week range | US$10.30 – US$30.99 |
| Volume | 425.28K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Bicara Therapeutics Inc.
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
Year: 2024
Bicara Therapeutics Inc. (BCAX) stock is trading at US$24.93, +0.39% from the previous close of US$24.83.
The market cap for Bicara Therapeutics Inc. (BCAX) stock is approximately US$1.58B.
The 52-week high for Bicara Therapeutics Inc. (BCAX) stock is US$30.99.
The 52-week low for Bicara Therapeutics Inc. (BCAX) stock is US$10.30.
Bicara Therapeutics Inc. (BCAX) does not currently pay a dividend.
Stay on top of BCAX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
